Anifrolumab (Saphnelo) March 6, 2024

March 6, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Nova Scotia effective March 1, 2024.

The public notice and listing criteria will appear on the Nova Scotia Pharmacare Programs website when the March Bulletin is posted.

Lupus Blog Articles: Lupus lorem ipsum dolor sit amet est requiem deste natur.

Scientists say they have identified a root cause of lupus — one that could pave the way for new treatments

Read

Belimumab (Benlysta) Now Approved in Saskatchewan, Nova Scotia, and New Brunswick for Lupus Nephritis

Read

Megakaryocyte: a new player in systemic lupus erythematosus

Read